Deninta 60mg Injection

About

Deninta 60mg Injection is a fully human monoclonal antibody that specifically targets and inhibits RANK ligand (RANKL), a crucial protein involved in the formation, function, and survival of osteoclasts. Osteoclasts are the primary cells responsible for bone resorption, the process by which bone tissue is broken down. By binding to RANKL, Deninta effectively prevents it from activating its receptor on osteoclasts and their precursors, thereby reducing osteoclast activity and bone turnover. This targeted mechanism leads to a significant increase in bone mineral density and a substantial reduction in the risk of various types of fractures, including vertebral, non-vertebral, and hip fractures. Administered via subcutaneous injection, it serves as a potent antiresorptive agent, offering a valuable therapeutic option for managing conditions characterized by excessive bone loss and fragility.

Uses

• Treatment of postmenopausal osteoporosis in women at high risk of fracture.
• Increase bone mass in men with osteoporosis at high risk of fracture.
• Treatment of bone loss in men receiving androgen deprivation therapy for non-metastatic prostate cancer.
• Treatment of bone loss in women receiving adjuvant aromatase inhibitor therapy for breast cancer.

Directions For Use

Administered via subcutaneous injection, typically once every six months. Follow healthcare provider's instructions precisely regarding dosage and administration technique.

Benefits

• Significantly reduces the risk of vertebral, non-vertebral, and hip fractures.
• Increases bone mineral density in various skeletal sites.
• Offers a convenient dosing schedule (biannual administration).
• Effective in preventing bone loss associated with certain cancer therapies.
• Improves bone strength and reduces bone pain in some conditions.
• Generally well-tolerated by many patients.

Side Effects

• Back pain
• Pain in extremities
• Musculoskeletal pain
• Hypercholesterolemia
• Cystitis
• Hypocalcemia (especially if pre-existing)
• Osteonecrosis of the jaw (rare)
• Atypical femoral fractures (rare)
• Serious infections (e.g., cellulitis)
• Dermatitis
• Eczema
• Pancreatitis (rare)

Safety Measures

• Alcohol - Moderate alcohol consumption is generally not contraindicated, but excessive intake can negatively impact bone health and overall treatment efficacy.
• Pregnancy - Contraindicated. May cause fetal harm. Women of childbearing potential should use effective contraception during and for at least 5 months after the last dose.
• Breastfeeding - Not recommended. It is unknown if Deninta is excreted in human milk; potential for serious adverse reactions in breastfed infants.
• Liver - No specific dose adjustment is required for patients with hepatic impairment. Use with caution and monitor for adverse effects.
• Kidney - Use with caution in severe renal impairment (creatinine clearance <30 mL/min) or dialysis patients due to increased risk of hypocalcemia. Calcium and vitamin D supplementation are crucial.
• Lung - No specific precautions for lung conditions. However, patients with severe respiratory impairment should be monitored for any unusual symptoms.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.